Synergy Between GLP-1 Receptor Agonists, Nutritional Therapy, and Physical Exercise in Optimising Body Composition and Cardiometabolic Health

Autores

  • Rodolfo Melo Raiol Scientific Director, Brazilian Diabetes Society (Pará Regional Chapter). Dean of the Postgraduate Program in Therapeutic Resistance Training and Exercise Physiology Applied to Special Populations, Centro Universitário do Estado do Pará.

DOI:

https://doi.org/10.36557/2674-9432.2026v5n1p2201-2205

Palavras-chave:

GLP-1, Weight Loss, Sarcopenia.

Resumo

Therapy with glucagon-like peptide-1 (GLP-1) receptor agonists has revolutionized the treatment of obesity and metabolic dysfunctions. However, the rapid weight loss induced by these drugs raises clinical concerns regarding depletion of fat-free mass and reductions in bone mineral density. This short communication synthesizes the recent literature on the physiology of GLP-1 receptor agonists, highlighting the non-negotiable need for multidisciplinary interventions. The integration of appropriate nutritional management with periodized resistance training emerges as the gold standard to mitigate the risk of secondary sarcopenia and to potentiate systemic adaptations to treatment.

Downloads

Não há dados estatísticos.

Referências

Westermeier F, Fisman EZ, et al. Glucagon-like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges. Cardiovasc Diabetol. 2025;24(1):44. doi: 10.1186/s12933-025-02608-9.

Olukorode JO, et al. Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders. Cureus. 2024;16(10):e72080. doi: 10.7759/cureus.72080.

Hira T, Pinyo J, Hara H. What Is GLP-1 Really Doing in Obesity? Trends Endocrinol Metab. 2020;31(2):71-80. doi: 10.1016/j.tem.2019.09.003.

Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. doi: 10.1002/oby.24336.

Christensen S, et al. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024;11:100121. doi: 10.1016/j.obpill.2024.100121.

Ard JD, Lewis KH, Moore JB. Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists. JAMA. 2024;332(1):16-18. doi: 10.1001/jama.2024.7062.

Mulcahy J, Delarosby A, Norwood T. Transforming Care: Implications of Glucagon-Like Peptide-1 Receptor Agonists on Physical Therapist Practice. Phys Ther. 2025;105(6):pzaf061. doi: 10.1093/ptj/pzaf061.

Gatto A, Liu K, Milan N, Wong S. The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. Curr Rev Musculoskelet Med. 2025;18(10):469-480. doi: 10.1007/s12178-025-09978-3.

Sandsdal RM, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41. doi: 10.1186/s12933-023-01765-z.

Lund MT, et al. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(2):172-180. doi: 10.1111/dom.12797.

Downloads

Publicado

2026-03-01

Como Citar

RAIOL, Rodolfo Melo. Synergy Between GLP-1 Receptor Agonists, Nutritional Therapy, and Physical Exercise in Optimising Body Composition and Cardiometabolic Health. Periódicos Brasil. Pesquisa Científica, Macapá, Brasil, v. 5, n. 1, p. 2201–2205, 2026. DOI: 10.36557/2674-9432.2026v5n1p2201-2205. Disponível em: https://periodicosbrasil.emnuvens.com.br/revista/article/view/693. Acesso em: 10 maio. 2026.

Edição

v. 5 n. 1 (2026): Periódicos Brasil. Pesquisa Científica - QUALIS A3

Seção

Comunicação Curta

Licença

Copyright (c) 2026 Rodolfo Melo Raiol

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Você tem o direito de:

  1. Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
  2. Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
  3. O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.  

 

De acordo com os termos seguintes:

  1. Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
  2. Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.